Respiratory syncytial virus, or RSV, is a common respiratory virus that typically causes mild, cold-like symptoms. According to the Centers for Disease Control and Prevention (CDC), most people who ...

A single RSV vaccine shot protects adults ages 60 or older from hospitalization and critical illness through two cold-and-flu seasons, according to a new multi-state study led by a Vanderbilt ...

The season of never-ending sneezing and stuffy noses is underway, sending Americans to pharmacy lines in hopes of keeping illness at bay with yearly shots. While flu and COVID-19 vaccines are an ...

After a 60-year scientific quest, the world has its first vaccine to protect against respiratory syncytial virus, or RSV -- and more are on the way. On Wednesday, the US Food and Drug Administration ...

New real-world data confirm the RSV vaccine offers strong protection for older adults across two winters, but highlight weaker responses in those with compromised immunity and cardiovascular disease.

For older adults, the vaccine against respiratory syncytial virus (RSV) appears to be most effective in the first year after administration, according to new research that shows the benefits of the ...

Estimated vaccine effectiveness was significantly lower for immunocompromised adults and those with CVD. HealthDay News — The respiratory syncytial virus (RSV) vaccine reduces RSV-associated ...

New research highlights the effectiveness of RSV preF vaccines in preventing severe respiratory infections in older adults. RSV is increasingly recognized as a substantial contributor to morbidity and ...

A Danish national registry trial shows the RSVpreF vaccine is highly effective at preventing severe RSV illness and related hospitalizations in older adults, offering real-world support for broader ...

Estimated vaccine effectiveness was significantly lower for immunocompromised adults and those with CVD. (HealthDay News) — The respiratory syncytial virus (RSV) vaccine reduces RSV-associated ...